Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Cardiovascular Conditions and Diseases
      • Digital Health
      • Health Policy
      • Immunity and Infectious Diseases
      • Joint Health and Mobility
      • Respiratory and Lung Health
      • Spinal Cord Injury and Rehabilitation
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Cardiovascular Innovation
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • Ovarian Cancer Research Centre
      • Vancouver Prostate Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • CST Cerner at VCH
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Education and Training
      • Communications and Branding
      • Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Innovation and Partnership
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Our Research
  3. Martin Gleave

Martin Gleave

Professor
Director, Vancouver Prostate Centre
Academic Appointment
Professor
Research Focus
Kidneys and Urinary System Cancers
Contact Info
m.gleave@ubc.ca

Biography

Dr. Martin Gleave is a distinguished professor and chairman of the Department of Urologic Sciences at the University of British Columbia (UBC) and a British Columbia Leadership Chair. He is co-founder and director of the Vancouver Prostate Centre, now a UBC and National Centre of Excellence. He is a surgeon-scientist whose research characterizes molecular mechanisms mediating treatment resistance in cancer, and designing co-targeting strategies to improve cancer control. He patented several anti-cancer drugs and founded OncoGenex Pharmaceuticals to develop OGX-011 and OGX-427, inhibitors of cytoprotective chaperones clusterin and Hsp27 which progressed to Phase III and Phase II trials world-wide. OncoGenex was awarded Canadian Biotech Company of the Year in 2010. Dr. Gleave also recently co-founded Sitka and Sustained Therapeutics.

In 2017, Dr. Gleave was appointed to the Order of Canada for his leadership role in developing new treatments for prostate cancer and for his research on mechanisms mediating treatment resistance in cancer. In 2020, he was inducted as a fellow in the National Academy of Inventors. Dr. Gleave is the recipient of numerous awards, including: the 2018 Dr. Chew Wei Memorial Prize in Cancer Research, the Huggins Medal from the Society of Urologic Oncology in 2018, the Richard Williams Award from the American Urological Association in 2017, the Barringer Medal from the American Association of Genitourinary Surgeons, the Eugene Fuller Award from the American Urological Association in 2013, the Aubrey Tingle Prize from the Michael Smith Foundation for Health Research, and the National Cancer Institute of Canada William Rawls Award for contributions to cancer control. He was appointed a Distinguished University Scholar at UBC in 2003 and awarded a B.C. Leadership Chair in 2005, the BC Biotech Award for Innovation and Achievement in 2006, and the BC Innovation Council Frontiers in Research Award in 2007.
 

Research Studies

Prostate Cancer

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Prostate Cancer

Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)

Prostate Cancer

Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER)

Prostate Cancer, Cancers

An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Prostate Cancer

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

News and Awards

Dr. Martin Gleave appointed to the Order of Canada

Jan 6, 2018

People in profile: Nader Al Nakouzi

Dec 4, 2015

A joint research laboratory to change the landscape of genomic and translational research

Sep 12, 2014

Local prostate cancer research excellence recognized internationally

Mar 20, 2014

Congratulations Dr. Martin Gleave - Aubrey J. Tingle Prize Winner

Oct 11, 2013

Publications

  • EMBO molecular medicine -

    Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling.

    Saxena N, Beraldi E, Fazli L, Somasekharan SP, Adomat H, Zhang F, Molokwu C, Gleave A, Nappi L, Nguyen K, Brar P, Nikesitch N, Wang Y, Collins C, Sorensen PH, Gleave M
  • Nature reviews. Urology -

    Towards precision oncology in advanced prostate cancer.

    Ku SY, Gleave ME, Beltran H
  • Cell -

    Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

    Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY
  • Cancer discovery -

    Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer.

    Annala M, Vandekerkhove G, Khalaf D, Taavitsainen S, Beja K, Warner EW, Sunderland K, Kollmannsberger C, Eigl BJ, Finch D, Oja CD, Vergidis J, Zulfiqar M, Azad AA, Nykter M, Gleave ME, Wyatt AW, Chi KN
  • The Journal of clinical investigation -

    Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models.

    Nappi L, Aguda AH, Nakouzi NA, Lelj-Garolla B, Beraldi E, Lallous N, Thi M, Moore S, Fazli L, Battsogt D, Stief S, Ban F, Nguyen NT, Saxena N, Dueva E, Zhang F, Yamazaki T, Zoubeidi A, Cherkasov A, Brayer GD, Gleave M
Working in the lab

Are you a researcher?

Update or create your researcher profile on our online directory.

Update Profile    Create New Profile

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • Twitter
  • LinkedIn

© 2023 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy